scholarly journals Increased levels of low-density lipoprotein cholesterol within the normal range as a risk factor for nonalcoholic fatty liver disease

Oncotarget ◽  
2015 ◽  
Vol 7 (5) ◽  
pp. 5728-5737 ◽  
Author(s):  
Dan-Qin Sun ◽  
Wen-Yue Liu ◽  
Sheng-Jie Wu ◽  
Gui-Qi Zhu ◽  
Martin Braddock ◽  
...  
Keyword(s):  
Risk Factor ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Normal Range ◽  
Nonalcoholic Fatty Liver

scholarly journals Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease

2016 ◽  
Vol 36 (8) ◽  
pp. 1213-1220 ◽  
Author(s):  
Zhenghui G. Jiang ◽  
Elliot B. Tapper ◽  
Margery A. Connelly ◽  
Carolina F. M. G. Pimentel ◽  
Linda Feldbrügge ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Very Low Density Lipoprotein ◽  
Low Density ◽  
Nonalcoholic Fatty Liver

scholarly journals Mean Arterial Pressure Is Related to Incident Nonalcoholic Fatty Liver Disease among the Nonobese Female with Normal Low-Density Lipoprotein Cholesterol Levels: A Large Cohort Study in China

2020 ◽  
Vol 2020 ◽  
pp. 1-9
Author(s):  
Shangbo Xu ◽  
Lan Chen ◽  
Danhua Hong ◽  
Lihua Yang ◽  
Xiaozhi Li ◽  
...  
Keyword(s):  
Liver Disease ◽  
Mean Arterial Pressure ◽  
Arterial Pressure ◽  
Cumulative Incidence ◽  
Fatty Liver Disease ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Nonalcoholic Fatty Liver

Aim. We aimed to demonstrate the independent effect of mean arterial pressure (MAP) on incident nonalcoholic fatty liver disease (NAFLD) among the nonobese Chinese with normal low-density lipoprotein cholesterol (LDL-C) levels. Methods. 16,153 nonobese participants without NAFLD at baseline were enrolled and then assigned to four groups by quartiles of MAP (Q1-Q4). A subgroup analysis by gender was also conducted. Participants were diagnosed with NAFLD by ultrasonography. Results. During a mean follow-up of 2.80 years, the cumulative incidence of NAFLD was 14.37 and the incidence rate was 513.17 per 10,000 person-years. The cumulative incidence of NAFLD for the whole population or gender groups gradually increased with the quartiles of MAP (all P<0.001). In the Q4 of MAP, the cumulative incidence of NAFLD for the whole population, male, and female reached up to 6.22 (5.75-6.70), 6.70 (6.21-7.19), and 5.69 (5.24-6.14), respectively. After adjustment for potential confounders, as compared with Q1, the hazard ratio for NAFLD was 1.328 (1.072-1.647), 1.625 (1.276-2.069), and 1.697 (1.231-2.340) for Q2, Q3, and Q4, respectively. In subgroup analysis, the respective hazard ratio for NAFLD in Q2, Q3, and Q4 of MAP was 1.760 (1.276-2.429), 2.080 (1.433-3.019), and 2.377 (1.452-3.890), compared with female in the Q1 of MAP. But MAP was not associated with incident NAFLD in male. Besides, MAP had a larger area under the receiver-operating characteristic curves than SBP or DBP, with optimal cutoff point of 88 mmHg in male and 89 mmHg in female. Conclusions. MAP is an independent predictor for incident NAFLD among nonobese female with normal LDL levels.

scholarly journals Effects of Epeleuton, a Novel Synthetic Second‐Generation n‐3 Fatty Acid, on Non‐Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers

2020 ◽  
Vol 9 (16) ◽  
Author(s):  
John Climax ◽  
Philip N. Newsome ◽  
Moayed Hamza ◽  
Markus Weissbach ◽  
David Coughlan ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Low Density Lipoprotein ◽  
Liver Stiffness ◽  
Density Lipoprotein ◽  
Nonalcoholic Fatty Liver ◽  
Cardiometabolic Markers ◽  
Post Hoc

Background Epeleuton is 15‐hydroxy eicosapentaenoic acid ethyl ester, a second‐generation synthetic n‐3 fatty acid derivative of eicosapentaenoic acid. The primary objective was to assess the effect of epeleuton on markers of nonalcoholic fatty liver disease (NAFLD) with post hoc analyses of cardiometabolic markers. Methods and Results In a multicenter, randomized, double‐blind, placebo‐controlled trial, 96 adults with nonalcoholic fatty liver disease and body mass index 25 to 40 were randomized in a 1:1:1 ratio to receive epeleuton 2 g/day, epeleuton 1 g/day, or placebo for 16 weeks. A total of 27% of patients had diabetes mellitus. Primary end points of changes in alanine aminotransferase and liver stiffness did not improve at week 16. Secondary and post hoc analyses investigated changes in cardiometabolic markers. Epeleuton 2 g/day significantly decreased triglycerides, very‐low‐density lipoprotein cholesterol, and total cholesterol without increasing low‐density lipoprotein cholesterol. Despite a low mean baseline hemoglobin A1C (HbA 1C ; 6.3±1.3%), epeleuton 2 g/day significantly decreased HbA 1c (−0.4%; P =0.026). Among patients with baseline HbA 1c >6.5%, epeleuton 2 g/day decreased HbA 1c by 1.1% ( P =0.047; n=26). Consistent dose‐dependent reductions were observed for fasting plasma glucose, insulin, and insulin resistance indices. Epeleuton 2 g/day decreased circulating markers of cardiovascular risk and endothelial dysfunction. Epeleuton was well tolerated, with a safety profile not different from placebo. Conclusions While epeleuton did not meet its primary end points on alanine aminotransferase or liver stiffness, it significantly decreased triglycerides, HbA 1C , plasma glucose, and inflammatory markers. These data suggest epeleuton may have potential for cardiovascular risk reduction and nonalcoholic fatty liver disease by simultaneously targeting hypertriglyceridemia, hyperglycemia, and systemic inflammation. Further trials are planned. Registration URL: https://www.clini​caltr​ials.gov ; Unique identifier: NCT02941549.

Sign in / Sign up

Export Citation Format

Share Document